Tempest Therapeutics — Valuation, Funding & Investors

Recent changes

Jun 23, 2026Jun 23, 2026Raised $4.1M SEC EDGAR Form D

Funding History

1 event · sources dated per row

Date	Event	Amount	Valuation	Investors	Source
Jun 23, 2026	funding round	$4.1M	—		SEC EDGAR Form D

Latest Pulse

Aug 21, 2026Three Biotechs File S-1s in the Same WeekTempest Therapeutics, Aptevo Therapeutics and Alzamend Neuro all filed S-1 registration statements this week, a reminder that the biotech IPO pipeline keeps moving even in a news cycle dominated by trillion-dollar AI listings.→

Coverage Timeline

newest first

Aug 21, 2026IPOThree Biotechs File S-1s in the Same Week→

All Coverage

IPO· Aug 21, 2026

Three Biotechs File S-1s in the Same Week

IPO

Three Biotechs File S-1s in the Same Week

Tempest Therapeutics, Aptevo Therapeutics and Alzamend Neuro all filed S-1 registration statements this week, a reminder that the biotech IPO pipeline keeps moving even in a news cycle dominated by trillion-dollar AI listings.

Aug 21, 2026DEEP DIVE

Related Companies

Same sector

Attovia Therapeutics Apnimed Braveheart Bio Latigo Biotherapeutics Scribe Therapeutics

Sources & methodologyshow

Where these figures come from

SEC EDGAR Form Dprimary source1 fact

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction